Quick Answer
NEUROCRINE BIOSCIENCES INC reported Total Revenue of $2.86 billion for fiscal year 2025.
NEUROCRINE BIOSCIENCES INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.86B +21.4% |
$2.36B +24.8% |
$1.89B +26.8% |
$1.49B +31.3% |
$1.13B +8.4% |
$1.05B +32.7% |
| Revenue (ASC 606) | $2.86B +21.4% |
$2.36B +24.8% |
$1.89B +26.8% |
$1.49B +31.3% |
$1.13B +8.4% |
$1.05B +32.7% |
| Net Income | $478.60M +40.2% |
$341.30M +36.7% |
$249.70M +61.6% |
$154.50M +72.4% |
$89.60M -78.0% |
$407.30M +1000.8% |
| Diluted EPS | $4.67 +41.9% |
$3.29 +33.2% |
$2.47 +58.3% |
$1.56 +69.6% |
$0.92 -77.9% |
$4.16 +966.7% |
| Total Assets | $4.63B +24.5% |
$3.72B +14.4% |
$3.25B +37.3% |
$2.37B +14.3% |
$2.07B +19.5% |
$1.73B +32.8% |
| Cash and Equivalents | $713.00M +206.0% |
$233.00M -7.2% |
$251.10M -4.5% |
$262.90M -22.9% |
$340.80M +82.1% |
$187.10M +66.6% |
| Stockholders Equity | $3.25B +25.6% |
$2.59B +16.0% |
$2.23B +30.7% |
$1.71B +24.3% |
$1.37B +22.0% |
$1.13B +76.8% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | $619.10M +8.5% |
$570.50M +127.4% |
$250.90M +0.8% |
$249.00M +142.9% |
$102.50M -37.1% |
$163.00M +125.4% |
| Shares Outstanding | 100.10M +0.7% |
99.40M +0.7% |
98.70M +2.3% |
96.50M +1.7% |
94.90M +1.5% |
93.50M +1.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $794.90M | +27.8% | +15.6% |
| Revenue (ASC 606) | September 30, 2025 | $794.90M | +27.8% | +15.6% |
| Net Income | September 30, 2025 | $209.50M | +61.4% | +94.9% |
| Diluted EPS | September 30, 2025 | $2.04 | +64.5% | +92.5% |
| Total Assets | September 30, 2025 | $4.27B | +20.7% | +9.7% |
| Cash and Equivalents | September 30, 2025 | $340.20M | -2.5% | +28.9% |
| Stockholders Equity | September 30, 2025 | $3.00B | +10.5% | +11.5% |
| R&D Expense | March 31, 2021 | $73.20M | +25.6% | +25.6% |
| Operating Income | September 30, 2025 | $239.00M | +30.0% | +64.1% |
| Shares Outstanding | September 30, 2025 | 99.70M | -1.5% | +0.7% |
- NEUROCRINE BIOSCIENCES INC reported Total Revenue of $2.86 billion for fiscal year 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +21.4% in Total Revenue compared to the prior fiscal year.
- NEUROCRINE BIOSCIENCES INC reported Revenue (ASC 606) of $2.86 billion for fiscal year 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +21.4% in Revenue (ASC 606) compared to the prior fiscal year.
- NEUROCRINE BIOSCIENCES INC reported Net Income of $478.60 million for fiscal year 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +40.2% in Net Income compared to the prior fiscal year.
- NEUROCRINE BIOSCIENCES INC reported Diluted EPS of $4.67 per share for fiscal year 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +41.9% in Diluted EPS compared to the prior fiscal year.
- NEUROCRINE BIOSCIENCES INC reported Total Assets of $4.63 billion for fiscal year 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +24.5% in Total Assets compared to the prior fiscal year.
- NEUROCRINE BIOSCIENCES INC reported Cash and Equivalents of $713.00 million for fiscal year 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +206.0% in Cash and Equivalents compared to the prior fiscal year.
- NEUROCRINE BIOSCIENCES INC reported Stockholders Equity of $3.25 billion for fiscal year 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +25.6% in Stockholders Equity compared to the prior fiscal year.
- NEUROCRINE BIOSCIENCES INC reported R&D Expense of $160.52 million for fiscal year 2018.
- NEUROCRINE BIOSCIENCES INC showed an increase of +31.8% in R&D Expense compared to the prior fiscal year.
- NEUROCRINE BIOSCIENCES INC reported Operating Income of $619.10 million for fiscal year 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +8.5% in Operating Income compared to the prior fiscal year.
- NEUROCRINE BIOSCIENCES INC reported Shares Outstanding of 100.10 million shares for fiscal year 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +0.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: